MOUNTAIN VIEW, Calif., Nov. 27, 2012 (GLOBE NEWSWIRE) -- ChemoCentryx, Inc. (Nasdaq:CCXI) announced today the initiation of a Phase I clinical trial for CCX872, the Company's next-generation of orally administered inhibitors targeting the chemokine receptor known as CCR2. The double-blind, placebo-controlled, single and multiple ascending dose study will evaluate the safety, tolerability and pharmacokinetics of CCX872 in 40 healthy adult subjects. ChemoCentryx' CCR2 program also includes CCX140, the Company's lead CCR2 inhibitor, currently in Phase II clinical trials for the treatment of diabetic nephropathy.
"The advancement of CCX872 into Phase I solidifies the Company's leadership position in developing experimental medicines targeting CCR2. We believe that developing two CCR2 inhibitors will enhance the flexibility within our CCR2 program, particularly in enabling options to pursue multiple medical indications for this mode of action," stated Thomas J. Schall, Ph.D., President and Chief Executive Officer of ChemoCentryx. "CCX872 deepens our development pipeline, and is a testament to our highly productive R&D platform."
The Company recently announced the successful completion of enrollment of the baseline 135 patients in the CCX140 Phase II trial in diabetic nephropathy and its plans to expand the study to enroll up to 270 patients, as allowed in the study protocol. Data from a 12-week analysis of this trial are anticipated in 2013. The Company further stated it may amend the Phase II trial to extend dosing for up to 52 weeks, allowing for an expanded data set regarding potential improvements in renal function to be obtained from this patient population as well.
ChemoCentryx, Inc. is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing orally-administered therapeutics that target the chemokine and chemoattractant systems in order to treat autoimmune diseases, inflammatory disorders and cancer. The chemokine system is a biological network that regulates inflammation via a collection of secreted chemokine molecules, or ligands, and their specific cell surface receptors. Based on its proprietary drug discovery and drug development platform, ChemoCentryx has generated multiple clinical and preclinical-stage programs, each targeting distinct chemokine and chemoattractant receptors with different small molecule compounds. The Company's most advanced drug candidate, vercirnon (also known as Traficet-EN, CCX282 or GSK1605786), a specific CCR9 inhibitor, completed a multi-national clinical trial, called PROTECT-1, in patients with moderate-to-severe Crohn's disease, where it demonstrated the ability to induce a clinical response and to maintain clinical remission, and is now in Phase III clinical development. The Company's lead independent drug candidate, CCX140, a CCR2 inhibitor, has been shown to be safe and well tolerated while demonstrating clinical activity on glycemic indices in a Phase II clinical trial in type 2 diabetics, and is now in Phase II clinical development for the treatment of diabetic nephropathy. In addition, CCX872, the Company's next-generation CCR2 inhibitor, is in Phase I clinical development. Other clinical programs include CCX354 (also known as GSK2941266), a CCR1 inhibitor which successfully completed a Phase II clinical trial for the treatment of rheumatoid arthritis, and CCX168, a C5aR inhibitor in Phase II clinical development for the treatment of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis. ChemoCentryx also has several programs in advanced preclinical development.
ChemoCentryx cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as "may," "could," "will," "would," "should," "expect," "plan," "anticipate," "believe," "estimate," "intend," "predict," "seek," "contemplate," "potential" or "continue" or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements are based on the Company's current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by ChemoCentryx that any of its plans will be achieved. Actual results may differ from those set forth in this release due to the risk and uncertainties inherent in the ChemoCentryx business and other risks described in the Company's filings with the Securities and Exchange Commission. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and ChemoCentryx undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included under the heading "Risk Factors" in ChemoCentryx's periodic reports filed with the Securities and Exchange Commission ("SEC"), including ChemoCentryx's Annual Report on Form 10-K for the year ended December 31, 2011 and Quarterly Report on Form 10-Q for the three-month period ended September 30, 2012, which are available from the SEC's website (www.sec.gov) and on ChemoCentryx's website (www.ChemoCentryx.com) under the heading "Investors." All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
CCXI - G
Source: ChemoCentryx, Inc.
CONTACT: Susan M. Kanaya Senior Vice President, Finance and Chief Financial Officer or Markus J. Cappel, Ph.D. Chief Business Officer 650-210-2900 firstname.lastname@example.org Burns McClellan Media Inquiries Justin Jackson 212-213-0006 email@example.com